Multitude Therapeutics

Antibody-drug conjugate (ADC) developer Adcendo has been busy during the last year and a half since the company raised a €31m ($32.3m) extension of the €51m ($53.2m) series A it originally raised in 2

The case for the US Food and Drug Administration to make Merck & Co., Inc. and Daiichi Sankyo Co., Ltd. ’s HER3-targeting antibody-drug conjugate (ADC) patritumab deruxtecan the first anti-HER3 ADC

Biopharmaceutical companies remained on the hunt for cancer antibody-drug conjugate assets this summer, as deals revolving around ADCs accounted for five of 12 cancer-related deals, according to Biome

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Lilly Teams With Oblique On Antibody Di